Last reviewed · How we verify

Firazyr — Competitive Intelligence Brief

Firazyr (ICATIBANT) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bradykinin B2 Receptor Antagonist. Area: Neuroscience.

marketed Bradykinin B2 Receptor Antagonist B2 bradykinin receptor Neuroscience Recombinant protein Live · refreshed every 30 min

Target snapshot

Firazyr (ICATIBANT) — Takeda. Firazyr works by blocking the action of bradykinin, a protein that causes blood vessels to swell and leads to symptoms of HAE.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Firazyr TARGET ICATIBANT Takeda marketed Bradykinin B2 Receptor Antagonist B2 bradykinin receptor 2011-01-01
Urinary Kallikrein Urinary Kallikrein Second Affiliated Hospital, School of Medicine, Zhejiang University marketed Serine protease / Kinin-kallikrein system activator Kininogen (substrate); B1 and B2 bradykinin receptors (downstream)
Firazyr Firazyr Sebastian Videla marketed B1 bradykinin receptor, B2 bradykinin receptor, B1 bradykinin receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bradykinin B2 Receptor Antagonist class)

  1. Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Firazyr — Competitive Intelligence Brief. https://druglandscape.com/ci/icatibant. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: